Just 20 seconds of speech could help detect type 2 diabetes using AI-based tool

From medicalxpress.com/news

by European Association for the Study of Diabetes 

Signs of type 2 diabetes can be detected in just a few seconds from the way someone talks, according to research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2.

The study, the largest of its kind, concludes that AI-based analysis of short recordings could be a fast, non-invasive and scalable screening tool for the condition.

Type 2 diabetes is becoming increasingly common, and early detection is key to preventing complications such as heart disease and nerve damage. Yet many cases go undetected, putting pressure on health care systems. In the U.K., for example, about 30% of cases are undiagnosed, and around 60% of the £10.7 billion the National Health Service (NHS) spends on diabetes each year goes toward managing complications.

Screening currently involves blood tests or appointments with primary care doctors.

For example, the NHS includes diabetes screening in the health checks it offers to people 40 and older every five years. But fewer than half of eligible adults (40.4%) attend these useful but time-consuming appointments, the study's authors say.

Previous research has linked type 2 diabetes to changes in speech, such as increased hoarseness and roughness and reduced control of breath and voice while speaking.

Researchers at deep tech company thymia, led by senior machine learning researcher Roseline Polle and senior research scientist Dr. Elisa Brann, worked with colleagues at RMIT University in Melbourne, Australia, to develop an AI model to detect these changes. They trained it on 63,283 voice samples from 21,129 people in the U.K. and U.S. who had reported whether they had been diagnosed with diabetes.

They then validated, or tested, the speech model on remote 20-second recordings of people reading one of Aesop's fables (short stories with animal characters and moral lessons).

The first of two evaluations compared the model's performance on recordings made by 7,319 adults in the U.K. (67% female; 45.8% age 40 or older; 217 reported having type 2 diabetes).

The speech model gave a higher risk score to people who reported having type 2 diabetes than to those who did not report having the condition 80% of the time, a result considered clinically useful.

The model performed well across different sexes and ages. However, performance was lower on recordings from Black participants. This was likely due to the low number of Black participants reporting type 2 diabetes, the authors say.

Performance was also lower on recordings from people with heart disease, high blood pressure or obesity. This is thought to be because these conditions often coincide with type 2 diabetes and may cause similar vocal changes.

The second evaluation involved a subgroup of 801 participants who took HbA1c tests at home within three months of the speech recording. (The HbA1c blood test measures average blood sugar levels over the past two to three months and is the gold-standard test for type 2 diabetes. It can also detect prediabetes, in which blood sugar levels are higher than normal but not high enough to be classified as diabetes.)

In this evaluation, the speech model gave a higher risk score to people with type 2 diabetes than to those who did not have the condition, based on HbA1c tests, 75% of the time. The sensitivity was 82% (that is, the model correctly identified 82% of the people with type 2 diabetes), and the false-positive rate was 47%.

The speech model was also able to distinguish among people at low, medium and high risk of type 2 diabetes, based on their HbA1c results. None of the people the model classified as low risk had blood results in the diabetic or prediabetic range.

The researchers conclude that type 2 diabetes can be detected at clinically useful levels from 20 seconds of speech.

Pending further clinical validation of the tool, one option would be for primary care doctors to use short recordings to triage patients. Those at higher risk could then be given blood tests to confirm their status. Speech-based screening would sit alongside blood testing, not replace it, the authors say.

Giedrė Čepukaitytė, a research scientist at thymia who will present the findings at EASD, says, "This is the largest real-world study of speech-based screening for type 2 diabetes to date that also checks the model's predictions against blood test results as well as against what people reported about their own diagnosis. Those flagged as higher risk by the model had blood results to match.

"This has the potential to change what screening looks like. A speech sample can be taken over the phone or through an app, so we can reach far more of the people who need a blood test than current approaches do, particularly those who never get to a health check.

"Our model opens a new route to screening for diabetes. It is not a replacement for a blood test, and it should never stop anyone who thinks they need one from getting one.

"Our next step is to test the model in clinical settings and to understand how well it works for every group of people, because a screening tool has to work for everyone."

https://medicalxpress.com/news/2026-09-seconds-speech-diabetes-ai-based.html

AI Predicts Diabetes Complications Years in Advance—Here’s How

From diabetesincontrol.com

Artificial intelligence is no longer a futuristic concept—it is changing how clinicians manage diabetes today. By analysing vast amounts of patient data, AI predicts diabetes complications years before they occur, giving healthcare teams the power to intervene early. Imagine if your doctor could warn you of kidney damage or vision loss long before symptoms appeared. That possibility is now within reach.

Table of Contents

• Introduction to Predictive AI in Diabetes Care
• How AI Detects Risks Before Symptoms Appear
• Real-World Applications and Success Stories
• Challenges, Limitations, and Future Potential
• Conclusion
• FAQs

Introduction to Predictive AI in Diabetes Care

Diabetes remains one of the most pressing global health challenges, with millions of people at risk of serious complications. Traditionally, clinicians rely on lab tests, clinical guidelines, and patient history to predict outcomes. However, AI predicts diabetes complications by processing electronic health records, lab values, genetic data, and lifestyle inputs more efficiently than humans ever could.

These algorithms identify patterns invisible to the human eye. For example, an AI system might notice subtle shifts in HbA1c trends, blood pressure fluctuations, or medication adherence data that point toward cardiovascular risk. In comparison, traditional approaches often wait until complications are already underway. By moving prediction years earlier, AI reshapes prevention.

For clinicians, this means earlier treatment decisions and more precise patient counseling. For patients, it may mean avoiding devastating outcomes like diabetic retinopathy or neuropathy that often reduce quality of life.

How AI Detects Risks Before Symptoms Appear

The power of AI lies in its ability to process massive datasets. Modern predictive models use machine learning to compare an individual’s health data against millions of other patients. This comparison allows the system to flag risks with high accuracy.

For example, deep learning algorithms can assess retinal scans and identify microscopic changes long before ophthalmologists can. Similarly, predictive AI can analyze kidney function markers, detecting early nephropathy years before conventional testing would raise alarms. These insights let doctors tailor treatment plans, adjust insulin regimens, or recommend lifestyle changes sooner.

Pharmaceutical companies are also integrating AI into drug research. Branded treatments like Ozempic (semaglutide) and Jardiance (empagliflozin) are being studied in real-world populations to see how AI models predict outcomes when patients use these therapies. This approach not only enhances personalized care but also supports evidence-based prescribing.

Additionally, Diabetes in Control articles have highlighted how AI-driven glucose monitoring systems help refine insulin therapy. When paired with continuous glucose monitors (CGMs), predictive software can reduce hypoglycaemia events and optimize time-in-range.

Real-World Applications and Success Stories

AI predicts diabetes complications with real-world success stories already reshaping practice. For instance, researchers at Google DeepMind developed an AI tool capable of forecasting acute kidney injury up to 48 hours in advance. Similar approaches are now being applied to chronic diabetes-related kidney disease.

Hospitals in Europe and North America are piloting AI platforms that predict foot ulcers before they develop. By combining wearable sensor data with predictive analytics, these tools lower the risk of amputations. Clinics also use AI to identify patients at risk for severe hypoglycemia by analyzing insulin dosing and continuous glucose monitoring data.

Pharma marketers are watching these trends closely. The integration of AI into clinical trials accelerates recruitment by identifying eligible patients earlier. Moreover, predictive tools help monitor real-world outcomes of drugs like Trulicity (dulaglutide) and Farxiga (dapagliflozin).

Beyond research, patients benefit from mobile health apps that integrate AI-driven insights. These tools provide personalized reminders, lifestyle tips, and risk forecasts, improving adherence and long-term outcomes. According to the National Institute of Diabetes and Digestive and Kidney Diseases, early intervention is critical in slowing progression. AI enhances the timing of that intervention.

Challenges, Limitations, and Future Potential

Despite the excitement, predictive AI is not without challenges. One major limitation is bias in datasets. If algorithms are trained on populations that lack diversity, predictions may not generalize across ethnicities or age groups. Additionally, while AI predicts diabetes complications effectively, it cannot always explain why the risk exists. Clinicians must still interpret results carefully.

Privacy also remains a concern. Using personal health data requires strict safeguards, especially when integrating wearable devices or genetic information. Patients need assurance that their data will remain confidential.

Another limitation is integration into clinical workflows. Doctors already face heavy time pressures. If AI systems are not user-friendly, they may add to the burden rather than reduce it. Fortunately, many health systems are now designing platforms that integrate seamlessly with electronic medical records.

Looking ahead, the potential remains enormous. As algorithms become more refined, predictive AI may provide patient-specific treatment roadmaps. A person diagnosed with Type 2 diabetes might one day receive a personalized care plan showing risks 5, 10, or even 15 years in advance. Linking these predictions to digital therapeutics and branded drug therapies may further transform outcomes. Patients seeking guidance should visit Healthcare.pro to connect with medical professionals.

Conclusion

AI predicts diabetes complications years in advance by analysing data that clinicians cannot process manually. From early detection of kidney disease to preventing foot ulcers, predictive algorithms give both patients and providers a critical head start. While challenges like bias, privacy, and workflow integration remain, the benefits outweigh the risks. As technology evolves, diabetes care will shift from reactive treatment to proactive prevention, changing the trajectory of millions of lives.

FAQs

How does AI predict diabetes complications?
AI analyses health data such as lab results, genetic markers, and wearable device readings to identify patterns that suggest future risks.

Which diabetes complications can AI predict most accurately?
AI models are especially effective at forecasting kidney disease, diabetic retinopathy, neuropathy, and hypoglycaemia events.

Are AI predictions better than traditional clinical tests?
They complement, rather than replace, clinical tests. AI can detect subtle changes earlier, but doctors must still confirm risks through standard diagnostics.

Do patients need special devices for AI predictions?
Not always. Some models use existing health records, while others rely on continuous glucose monitors or smart wearables.

Is predictive AI safe for patient privacy?
Yes, when used under strict data security standards. However, patients should always confirm how their data is handled.

Disclaimer

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.

https://www.diabetesincontrol.com/ai-predicts-diabetes-complications-years-in-advance-heres-how/ 

New AI Model Predicts Diabetes Risk Early by Tracking Glucose Fluctuations

From diabetesincontrol.com

What if your blood sugar patterns could tell the future of your health—before you even feel sick? A ground-breaking artificial intelligence (AI) model may do exactly that. Researchers have developed an algorithm capable of predicting diabetes risk in its earliest stages, using subtle changes in glucose fluctuations long before any clinical symptoms appear. This innovation could shift how clinicians diagnose and treat prediabetes and Type 2 diabetes, catching it sooner and preventing long-term complications.

How AI Uses Glucose Patterns to Predict Diabetes

AI is transforming healthcare by recognizing patterns that humans might miss. In this case, the model was trained on massive datasets from individuals using continuous glucose monitoring (CGM) devices. Instead of waiting for fasting glucose levels or A1C to rise, the algorithm flags risk based on the variability and spikes in glucose over time.

While traditional diagnostics rely on singular lab values, this AI model looks at how a person’s glucose changes throughout the day and night. Even slight, repeated elevations after meals—often dismissed as normal—can indicate rising diabetes risk. The system identifies when these postprandial spikes begin to follow patterns commonly seen in people who later develop Type 2 diabetes.

This approach provides a dynamic view of metabolic health rather than a static snapshot. In many ways, it’s like tracking the tremors before an earthquake—giving clinicians a valuable chance to intervene before serious damage occurs.

The Role of Continuous Glucose Monitoring and Machine Learning

Central to this breakthrough is the synergy between CGM devices and machine learning algorithms. CGMs, such as those made by Dexcom or Abbott’s FreeStyle Libre, provide round-the-clock glucose data, which can be fed into the AI system. The model uses supervised learning to compare new user data with historical profiles of individuals who progressed to Type 2 diabetes.

Over time, the AI learns to recognize subtle red flags—like late-night spikes or prolonged post-meal elevations—that might otherwise go unnoticed. Additionally, the system adjusts its risk scoring based on individual variation, such as age, activity levels, and even medication use, including metformin or GLP-1 receptor agonists like Ozempic or Mounjaro.

Importantly, the model has demonstrated high accuracy in identifying individuals at high risk, even when their A1C levels were technically within normal range. This opens the door for earlier preventive care, such as dietary counselling or lifestyle interventions, which are often more effective when implemented early.

For clinicians and patients alike, this is a significant step forward. By transforming raw glucose data into actionable insight, AI empowers a more proactive and personalized form of diabetes care.

Clinical Impact: Earlier Diagnosis, Better Outcomes

The promise of early detection extends well beyond prediction. Catching diabetes risk early allows patients to make changes when those changes can have the biggest impact. For example, a patient whose glucose data hints at prediabetic patterns may benefit from targeted nutritional support or a structured exercise plan. These strategies can delay or even prevent progression to Type 2 diabetes.

Moreover, early identification means avoiding the cascade of complications—retinopathy, nephropathy, and cardiovascular issues—that often accompany undiagnosed or untreated diabetes. For healthcare systems, this translates to reduced costs, fewer emergency visits, and improved long-term health outcomes.

Some health organizations are already exploring integration of AI-driven glucose analysis into primary care workflows. For instance, patients undergoing annual check-ups might be temporarily fitted with a CGM to collect data over a few weeks. That data would then be analysed by the AI model to determine their risk profile.

Additionally, early risk stratification could help providers prioritize who receives more intensive interventions, especially in resource-limited settings. This personalized approach to prevention could reshape how we manage diabetes on both the individual and population level.

What Patients and Providers Should Know

As promising as this new AI model may be, it raises important questions about data privacy, access, and equity. Not all patients currently have access to CGMs or health systems equipped to implement AI screening tools. Therefore, advocacy around broader insurance coverage for CGMs and digital health tools will be crucial.

Patients should also be aware that AI doesn’t replace clinical judgment. Instead, it enhances decision-making by offering earlier, more precise indicators of diabetes risk. Combined with human oversight, this technology has the potential to reshape the way we approach metabolic health.

For healthcare providers, integrating AI-driven models may require updated workflows, training, and reimbursement pathways. However, the benefits—better predictive accuracy, earlier interventions, and more personalized care—make it a worthwhile investment.

As digital health tools become more widespread, collaboration between data scientists, clinicians, and patients will be essential. Together, they can ensure that AI works for everyone, not just the digitally savvy or well-insured.

Conclusion

The ability to predict diabetes risk before symptoms even appear could mark a turning point in chronic disease prevention. Through AI-powered analysis of glucose fluctuations, clinicians can now spot early warning signs that traditional methods might miss. While the technology is still evolving, it represents a new era of proactive, personalized diabetes care—one where prevention truly starts before diagnosis.

FAQs

How does the AI model predict diabetes risk?
It analyses glucose fluctuations from CGM data, identifying patterns linked to future diabetes development, even before symptoms appear.

Can this technology replace traditional lab tests?
No. It complements standard diagnostics like A1C by offering earlier, more dynamic insights into glucose behavior.

Is this AI model available to the public?
Currently, it’s being tested in clinical settings and research institutions, but broader adoption is likely in the coming years.

Does insurance cover the use of CGMs for prevention?
Coverage varies by provider and region. However, advocacy is growing to expand access for preventive purposes.

Where can I go for personalized advice based on my glucose data?
Always consult your healthcare provider or a licensed professional via Healthcare.pro for individual guidance.

---

Disclaimer

“This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.”

https://www.diabetesincontrol.com/new-ai-model-predicts-diabetes-risk-early-by-tracking-glucose-fluctuations/ 

How Artificial Intelligence Is Changing Diabetes Care

From diatribe.org

Key takeaways:

• New AI tools are emerging in diabetes care and research to analyse data in new ways
• A panel of experts said that the growing availability of these AI tools has the potential to increase the quality of diabetes care. 
• Security and privacy concerns persist and should be addressed for wider adoption of the new technology.

The emergence of artificial intelligence in healthcare has put diabetes care at the precipice of tremendous change, potentially offering people more control over their health and greater access to new options to manage their glucose levels and all aspects of their lives. 

Such topics were at the forefront of an expert panel discussion on the opening day of the ADA 2024 Scientific Sessions conference in Orlando, Florida, asking the question, “How will Artificial Intelligence Change Clinical Practice?” The answer was unequivocal: AI promises to deliver significant improvements in diabetes care for those who avail themselves of digital tools, such as apps, pumps, AID systems and CGMs.

For those now using continuous glucose monitors, the machine learning revolution is already under way, according to the expert panellists. The improved time in range that most people with CGMs experience from tracking their glucose levels is the basic building block of future AI, data-driven advancements.

The future of diabetes data science

While AI has meaningful uses across health care in general — using pattern recognition, large language models, expert systems and decision support — diabetes care is uniquely positioned to benefit from AI advances since technology has made it so quantifiable, said Dr. Boris Kovatchev of the University of Virginia. 

“AI applications are rapidly entering healthcare,” Kovatchev said. “Generative AI and large language models are at the forefront of this trend. Diabetes is one of the best quantified human conditions. Hence, diabetes care is making rapid progress with numerous applications.”

Advances that he listed include:

• Detection and prediction of events, classification and tracking disease progression,
• AI powering decision support systems,
• AI-driven neural network automated insulin delivery,
• AI-augmented clinical trials – “a most promising future,” he said.

Of particular note, Kovatchev presented results from the Virtual DCCT Project to illustrate how AI can augment clinical trials by reproducing virtual CGM traces for each DCCT participant to provide insights into how CGM metrics could relate to the risk for chronic complications and severe hypoglycaemia in the historic study data. 

Not only did the AI trial reproduce A1C outcomes of the groups in the treatment groups in the original DCCT trial, but Kovatchev showed how the AI-augmented study of the decades old trial was able to measure a “simulated” Time in Range that was significantly higher (60%-70%) in the “virtual” intensive treatment group compared to the “virtual” conventional treatment group.  

AI and diabetes devices

Dr. Peter Jacobs, director of the Artificial Intelligence for Medical Systems lab at Oregon Health & Science University, predicted a future in which a person with diabetes might be able to use an AI-enabled “automated hormone delivery system.” 

This hypothetical future system would take much of the guesswork and mental labor out of daily management by including:

• Automatic detection and dosing of insulin and pramlintide for meals
• Automatic detection and prevention of DKA with a ketone monitor
• Automatic detection of exercise and adjustment of insulin and glucagon to avoid hypoglycaemia
• Automatic pattern detection to forecast and solve future problems
• Automatic adjustment of insulin dosing in response to cyclical events, such as weekends, menstruation, or illness.
• Digital twin-based decision support on medication choices, exercise guidelines and nutrient intake
• Automated detection of pump occlusion, sensor failures and other system faults
• Alert system and user interface that learns to optimally satisfy the user

This future world is not yet here, but it might not be far off, said Jacobs, who has been working with his team to develop advanced control systems for the delivery of insulin and glucagon, among other uses of AI assistance in diabetes care and research. 

“There’s a lot of new technologies coming out right now that could significantly help people,” he said. “We’re at a time right now where you have an explosion of accurate sensors, an explosion of computation and access to all these tools. Combining computation with sensors, it's a tremendous opportunity and an exciting time for patients.” 

Connecting teams to deliver more powerful care

The third panellist at the session, Dr. Mudassir Rashid of the Illinois Institute of Technology, spoke about his research into how the use of AI impacts multidisciplinary team approaches to healthcare. The complexity of diabetes care and its need for coordination between healthcare teams make it well suited for AI enhancements, he said.

Rashid said the safe use of AI must include protections for data security and privacy as well as efforts to build trust in AI systems. In addition, he said, it is important to be aware of the potential for bias of algorithms and have clinicians ensure proper diagnosis, care and patient outcomes.

“People should be excited about the fact that it’s going to empower them,” he said of the emergence of AI technology in diabetes care. “It’s going to give them a lot more knowledge and insights about the chronic disease outside of the clinical setting, so they can get information outside of seeing their doctor. And this can also inform their diabetes treatment and care.” 

Security and privacy

Such data, Rashid explained, can be analysed by AI tools and then be available for the patient’s health care team and caretakers to glean specific insights about the individual to offer them better care. 

“There are some concerns with data privacy and security, but the best way to overcome them is to demonstrate to patients that there are safeguards,” he said. “It’s their data, it belongs to the patients, so more has to be done in securing their privacy. I’m optimistic that these are  technical and regulatory challenges that we can overcome. This is going to substantially improve care for people with diabetes.” 

https://diatribe.org/diabetes-technology/how-artificial-intelligence-changing-diabetes-care 

The Danger of Medical Advice from AI

From diabetesincontrol.com

Introduction

Artificial Intelligence is transforming the healthcare landscape with impressive speed. Yet, as more patients and even healthcare professionals turn to AI tools for support, one pressing question emerges: Can medical advice from AI be trusted? Although AI has demonstrated remarkable capabilities in diagnostics, data analysis, and predictive modelling, relying solely on AI-generated guidance can present serious risks—especially for chronic conditions like diabetes. This article explores the inherent dangers of medical advice from AI and how clinicians can balance innovation with safety.

Table of Contents

• The Rise of AI in Healthcare
• Key Risks of Medical Advice from AI
• Case Studies and Real-World Implications
• How Clinicians Can Responsibly Integrate AI

The Rise of AI in Healthcare

AI technology has surged across every aspect of healthcare, from virtual health assistants to AI-powered diagnostic tools. Machine learning algorithms can sift through vast amounts of patient data, flagging potential diagnoses or recommending treatment plans. Some platforms claim to rival or even outperform human physicians in certain specialties, particularly in imaging and pathology.

While these tools offer undeniable benefits, many are not yet regulated or peer-reviewed in ways that ensure clinical safety. Patients using chatbots or symptom checkers may misinterpret suggestions, leading to delays in proper diagnosis or inappropriate medication use. Furthermore, the absence of contextual patient information often means AI can make recommendations that are technically sound but clinically inappropriate.

Key Risks of Medical Advice from AI

AI models can be impressive, but they are only as good as the data they are trained on. For diabetes care, a poorly trained model might generalize treatment strategies or overlook the nuanced factors that a trained endocrinologist would consider—such as medication interactions, lifestyle, or comorbidities.

A primary concern is the illusion of accuracy. Patients may see AI as objective and mistake confidence for correctness. In one study published in JAMA Network Open, researchers found that while some AI-generated responses to medical questions were judged as more empathetic than doctors’, they still occasionally delivered incorrect or unsafe information.

Moreover, AI platforms can perpetuate bias. If historical healthcare data contain disparities, AI might reinforce those same issues in its advice. This could especially affect underrepresented groups in diabetes research, including communities of colour, the elderly, and rural populations.

Data privacy is another major issue. Many AI tools, particularly consumer-facing apps, collect sensitive health data without clearly defined usage limits or sufficient encryption. Misuse or leakage of this data could have devastating consequences.

Case Studies and Real-World Implications

Consider a patient with type 2 diabetes who uses an AI chatbot to adjust their insulin dosage. The AI may suggest a modification based on blood sugar trends, but fail to account for recent changes in diet, stress, or exercise. A single inaccurate suggestion could lead to hypoglycaemia or ketoacidosis—potentially life-threatening situations.

In another case, a clinician might rely on an AI tool for interpreting lab results. If the algorithm misinterprets data due to an outlier or missing variable, treatment could be delayed or misdirected. Although many tools are designed to assist, not replace, human judgment, time-strapped practitioners may inadvertently lean too heavily on automation.

Even widely trusted platforms have stumbled. In 2023, a major health chatbot was found to offer incorrect cancer screening guidance, despite being trained on verified data. The issue was traced back to poorly weighted confidence scoring and lack of recent guideline updates. These examples underscore why direct clinical oversight remains essential.

How Clinicians Can Responsibly Integrate AI

Despite the dangers, AI has tremendous potential when used responsibly. Clinicians should treat AI-generated advice as one of many tools in their decision-making toolkit—not a replacement for professional judgment.

The first step is education. Understanding how a particular AI tool works, what data it uses, and its known limitations can help clinicians gauge when and how to apply it. Many leading platforms now offer transparency reports detailing their data sources, algorithm logic, and update cycles.

Secondly, clinicians should encourage patients to discuss AI-generated advice during appointments. This creates an opportunity to correct misinformation and help patients interpret findings in context. Platforms like Health.HealingWell.com offer supportive forums where patients can share their experiences and clinicians can clarify misconceptions.

It’s also important to monitor outcomes. By tracking whether AI-supported decisions result in better care or pose recurring risks, healthcare teams can continuously evaluate which tools are worth integrating.

Lastly, working with regulatory and data ethics bodies ensures that AI tools meet appropriate clinical standards. As AI becomes more embedded in healthcare, organizations like the FDA and WHO are developing frameworks for safe deployment.

Conclusion

Medical advice from AI is not inherently dangerous—but blind reliance on it can be. For patients with chronic conditions like diabetes, the stakes are high and missteps can be costly. Clinicians must remain the final authority, leveraging AI to support rather than replace their expertise. By educating themselves and their patients, monitoring the quality of AI tools, and participating in ethical oversight, healthcare providers can harness the benefits of AI while minimizing the risks.

This content is not medical advice. For any health issues, always consult a healthcare professional

https://www.diabetesincontrol.com/the-danger-of-medical-advice-from-ai/